Oseltamivir–zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses

This publication has 11 references indexed in Scilit:

• Oseltamivir–zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections
  Antiviral Research, 2012
• Effect of Oseltamivir, Zanamivir or Oseltamivir– Zanamivir Combination Treatments on Transmission of Influenza in Households
  Antiviral Therapy, 2012
• An Open-Label Crossover Study To Evaluate Potential Pharmacokinetic Interactions between Oral Oseltamivir and Intravenous Zanamivir in Healthy Thai Adults
  Antimicrobial Agents and Chemotherapy, 2011
• Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors
  The Journal of Infectious Diseases, 2011
• Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial
  PLOS Medicine, 2010
• Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration
  Antimicrobial Agents and Chemotherapy, 2010
• Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro
  PLOS ONE, 2010
• Neuraminidase Inhibitors for Influenza
  New England Journal of Medicine, 2005
• Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
  Clinical Pharmacokinetics, 1999
• Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrate
  Analytical Biochemistry, 1979